- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00906672
Medico Economic Evaluation of Dermal Substitute Integra® for Coverage of Inferior Limb Traumatic Skin Loss (INTEGRA®)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Traumatic skin loss with bone or tendon exposure essentially affects inferior limbs. There are considered serious as they often lead to functional and esthetical consequences, and they generally affect young people.
Flap surgery is the treatment of reference for these skin losses. This technique requires expensive material and a lot of medical staff. The intervention and duration of hospitalisation are often long with heavy medication. Post surgery complications or disabling sequelea involve surgical re-interventions which increase duration of hospital stay and medical staff availability.
The dermal substitute Integra® (Integra LifeSciences Corporation) is an advanced wound care device comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan and a semi-permeable polysiloxane (silicone layer). This medical device allows formation of a neoderm. The silicon layer is a temporary layer which is removed when the neoderm is totally built. This surgery is fast, non-invasive, with short hospital stay and limited complications which can be treated easily.
Objective of the study: to assess medico-economic interest of innovative surgery using dermal substitute Integra® compared to the reference using flap surgery in the treatment of traumatic skin loss of inferior limbs. Assessment will be based on re-interventions incidence, long-term functional and esthetical scar results and total cost of each technique.
Study design: multicenter, randomized, open label, parallel design, clinical trial in 12 French plastic surgery / burn care centres.
Planned number of enrolled patients: 120 (80 patients receiving Integra® and 40 patients receiving the flap surgery). Patients will be randomized in 1 of the 2 groups, with an imbalance in favour of the innovative technique.
Duration of enrollment: 24 months Duration of patient follow up: 18 months
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Besançon, France, 25030
- University Hospital
-
Bordeaux, France
- Universiy Hospital Bordeaux,
-
Clermont-Ferrand, France, 53003
- University Hospital
-
Grenoble, France, 38043
- University Hospital
-
Montpellier, France, 34295
- University Hospital
-
Nice, France, 06003
- Saint Roch Hospital
-
Pointe-à-Pitre, France, 97159
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient with skin loss traumatic or chronic wound
- wound located from mid third of the leg to distal extremity of feet
- with muscle and/or tendon and/or bone and/or articulation exposure
- requiring a first surgical intervention for the coverage of the skin loss
- patient eligible to the Integra® surgery techniques
- patient with social security affiliation
- written informed consent signed by the patient or representative
Exclusion Criteria:
- Bone fracture located in the skin loss
- Non traumatic wound
- Wound with muscle exposure only
- Immunocompromised patient
- Allergy to bovine collagen, glycosaminoglycans or silicon
- patient with an healthstate that compromise the 18 months Follow-up
- pregnant women / who intend to become pregnant within the 18 months of follow-up
- Patient under administrative or legal supervision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INTEGRA®
|
A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured.
A negative pressure bandage is placed on the wound.
7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
|
Active Comparator: Flap technique
|
A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of at least one complication requiring a surgical re-intervention
Time Frame: Within the first 18 months after surgery
|
Within the first 18 months after surgery
|
Persistence of an important / major trouble of the scar measured by a "scar-trouble scale" filled in by the patient.
Time Frame: at 18 month-follow up
|
at 18 month-follow up
|
Auto-evaluation of patient's scar esthetical result with a visual analog scale.
Time Frame: at 18 month-follow up
|
at 18 month-follow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of all post surgical complications
Time Frame: Within the first 18 months after surgery
|
Within the first 18 months after surgery
|
Duration of hospitalization and healing
Time Frame: Within the first 18 months after surgery
|
Within the first 18 months after surgery
|
Period until return to work and re-start of daily activities
Time Frame: Within the first 18 months after surgery
|
Within the first 18 months after surgery
|
Ïntensity of scar pain during cares evaluated with a visual analog scale and quality of life (EuroQol)
Time Frame: Within the first 18 months after surgery
|
Within the first 18 months after surgery
|
Human and medical requirements
Time Frame: Within the first 18 months after surgery
|
Within the first 18 months after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Geneviève CHENE, MD-PhD, USMR (University Hospital, Bordeaux)
- Study Director: Vincent CASOLI, MD-MHD, University Hospital, Bordeaux
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2008/26
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leg Injuries
-
QualissimaDTA MedicalUnknown
-
Tribhuvan University Teaching Hospital, Institute...UnknownArthroplasty, Replacement, Knee | Leg InjuryNepal
-
Nationwide Children's HospitalNot yet recruiting
-
Faculdade de Ciências Médicas da Santa Casa de...Completed
-
Northern Vermont UniversityCompletedInjury;Sports | Injury, Knee | Injury, Ankle | Injury LegUnited States
-
Caitlin ConleyThe Cleveland ClinicRecruitingWounds and Injuries | Knee Injuries | Patellar Dislocation | Leg InjuryUnited States
-
SolasCure LimitedCompletedVenous Leg Ulcer | Leg Injuries and DisordersUnited States, Hungary, United Kingdom
-
Twin Cities OrthopedicsRecruiting
-
St. Olavs HospitalRosenborgklinikkenRecruiting
-
University Hospital, ToulouseCompleted
Clinical Trials on INTEGRA®
-
Hamilton Health Sciences CorporationAFP Innovation Fund; Stem Cell Network; Ontario Institute for Regenerative MedicineNot yet recruiting
-
Georgetown UniversityLifeNet HealthUnknownWounds | Chronic Wounds | Nonmalignant ConditionUnited States
-
HealthPartners InstituteTerminated
-
Integra LifeSciences CorporationCompletedHernia | Pathological Conditions, Anatomical | Hernia, Abdominal | Hernia, VentralUnited States
-
Integra LifeSciences CorporationCompletedNeuropathic Diabetic Ulcer - FootUnited States, Netherlands Antilles
-
Istituti Clinici Scientifici Maugeri SpACompleted
-
Impulse DynamicsRecruitingHeart Failure | Arrhythmias, Cardiac | Ventricular Fibrillation | Ventricular Tachycardia | Implantable Defibrillator User | Heart Failure With Reduced Ejection Fraction | Ischemic Cardiomyopathy | Sudden Cardiac Arrest | Non-ischemic Cardiomyopathy | CCM TherapyUnited States
-
Duke UniversityOdessey II SolutionsWithdrawnOxygen Delivery Systems at Altitude
-
Berufsgenossenschaftliche Unfallklinik LudwigshafenCentral Institute of Mental Health, MannheimRecruitingCicatrix | Nonsuicidal Self Injury | Stigmatization | Skin TransplantationsGermany
-
Wake Forest University Health SciencesTerminatedHead and Neck CancerUnited States